Overview:
Companion animals now account for one-third of the world market for animal
health products. Sales were $4.5 billion in 2003 and Animal Pharm Reports
forecast that they will rise to $5.9 billion by the end of the decade. The
sector attracts the bulk of R&D investment, and there is a range of new
products in companies’ development pipelines. At the same time, market leading
products will come off-patent, and generics companies are already planning
launches of competitor brands.
This report analyses all aspects of this highly dynamic market, including:
- Market sizes and profiles in the 10 leading national markets, accounting
for 85% of the world market
- Reviews of product sectors, including the products on the market, recent
developments, generic activity and future prospects
- Market drivers, including investments in R&D, the next generation of
generic products and regulatory developments
- Profiles of the 10 leading companion animal companies, accounting for
two-thirds of world sales
- The most important companion animal health problems.
Executive Summary:
Products for use in companion animals have been the main driver of growth in
an otherwise flat market for veterinary medicines over the past decade. This
report analyses the size and structure of the companion animal market,
identifies major product segments and the geographical spread of sales in the
sector, and profiles the businesses of leading companies involved in the market.
Chapter 1 of the study provides a brief overview of major health problems
affecting the three key companion animal species (dogs, cats and horses), and
identifies the type of products used to prevent, treat or control them. Viral,
bacterial and parasitic infections are among the most prevalent challenges faced
by companion animals. Chronic, often age-related, conditions such as
cardiovascular disease and cancer are increasingly prevalent in dogs and cats,
however, as the longevity of pets continues to rise, with cancer now the leading
disease-related cause of mortality in the US canine population.
Products used to prevent, treat or control disease in companion animals are
addressed in Chapter 2 of the report. The main focus of this section is product
groupings responsible for major shares of the companion animal market in value
terms, including antiparasitics, anti-infectives, anti inflammatories and
biologicals. Smaller segments in which significant launch activity has been
witnessed recently or is expected in future are also addressed.